Adverse Events Related to Azathioprine Use in Patients With Inflammatory Bowel Disease: A Real‐World Cohort Study
Gastroenterology Research and Practice · 2026-01 · 2026 (1)
DOI: 10.1155/grp/1808791 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Gastroenterology Research and Practice, online erschienen am 10.04.2026. Verfasst von Mukesh Kumar Ranjan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Chitwan Medical College, Bharatpur, Chitwan, Nepal, cmc.edu.np. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background and Aim Azathioprine is one of the commonly used maintenance therapies in patients with inflammatory bowel disease (IBD), specifically in low‐ and middle‐income countries. However, the use of thiopurines is questioned due to safety concerns. We aimed to assess the adverse event (AE) profile of azathioprine in IBD patients.
Methods
This was a single‐centre retrospective study. All the consecutive patients treated with azathioprine were considered for this study. Data were collected from prospectively maintained IBD files. The primary objective was to assess the adverse events arising due to azathioprine use. The AEs were defined as per standard definitions. The relation between the AE and dose and duration of azathioprine use was assessed.
Results
Among 48 patients [UC: 20 (41.7%) and CD: 28 (58.3%)] included, 30 (62.5%) were male. The mean age and the disease duration were 41.2 ± 15.7 years and 15 (5–40.5) months, respectively. The initiation and maximum dose of azathioprine were 0.91 ± 0.15 and 2.04 ± 0.58 mg/kg. The median thiopurine treatment duration was 6.5 (2.25–15), 11.5 (3.5–23.5) and 5.75 (2–12.5) months, respectively, in the whole cohort, UC and CD. A total of 25 (52.1%) patients developed adverse events [8 (40.0%) in UC and 17 (60.7%) in CD]. The commonest AEs were leukopenia in 15 (31.2%), GI intolerance in 5 (10.4%), arthralgia in 4 (8.3%), hepatitis in 3 (6.2%) and hair fall in 2 (4.1%) patients. No infection or acute pancreatitis episode or malignancy was reported. A total of 16 (33.3%) patients stopped azathioprine. AEs were the most common cause of azathioprine withdrawal in 12 (25.0%). No serious adverse event was reported.
Conclusion
Adverse events are common and lead to therapy discontinuation in one fourth of the IBD patients on azathioprine. The commonest adverse events are leukopenia, GI intolerance, arthralgia, hepatitis, and hair fall.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Chitwan Medical College, Bharatpur, Chitwan, Nepal, cmc.edu.np.
- Department of Gastroenterology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal, teachinghospital.org.np.
ORCID-Profile: Mukesh Kumar Ranjan, Pradeep Neupane, Bigyan Maharjan, Manoj Lamsal, Bikash Poudel
Zitieren
APA
Ranjan, M. K., Neupane, P., Maharjan, B., Lamsal, M., & Poudel, B. (2026). Adverse Events Related to Azathioprine Use in Patients With Inflammatory Bowel Disease: A Real‐World Cohort Study. Gastroenterology Research and Practice, 2026(1). https://doi.org/10.1155/grp/1808791
Vancouver
Ranjan MK, Neupane P, Maharjan B, Lamsal M, Poudel B. Adverse Events Related to Azathioprine Use in Patients With Inflammatory Bowel Disease: A Real‐World Cohort Study. Gastroenterology Research and Practice. 2026;2026(1). doi:10.1155/grp/1808791
BibTeX
@article{Ranjan2026,
author = {Ranjan, Mukesh Kumar and Neupane, Pradeep and Maharjan, Bigyan and Lamsal, Manoj and Poudel, Bikash},
title = {Adverse Events Related to Azathioprine Use in Patients With Inflammatory Bowel Disease: A Real‐World Cohort Study},
journal = {Gastroenterology Research and Practice},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/grp/1808791}
}
EUVIMED